<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02064699</url>
  </required_header>
  <id_info>
    <org_study_id>I10002 QUANTIC-R+</org_study_id>
    <nct_id>NCT02064699</nct_id>
  </id_info>
  <brief_title>Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.</brief_title>
  <acronym>QUANTIC-R+</acronym>
  <official_title>Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high
      morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D + and D-25% R +
      develop CMV. The number of available antiviral drugs is reduced and noticeable side effects
      (neutropenia, renal toxicity) lead to premature discontinuation of therapy or the use of
      reduced doses that promote non-response to treatment and the emergence of resistance. In
      case of neutropenia, there are more an increased risk of secondary rejection due to the
      reduction of immunosuppressive treatment rendered necessary by the haematological reached.

      Rational use of these molecules is necessary with essential today as the optimal duration of
      prophylaxis primary issues and the prophylaxis of recurrences in case of CMV infection
      reported in.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      QuantiFERON-CMV ® is a fast and standardized test that evaluates the CMV specific cellular
      immunity measuring the amount of secreted Interferon gamma (IFN gamma) in plasma by ELISA.
      It uses more epitopes of proteins including CMV glycoprotein B (gB), protein IE-1 and
      protein pp65 and protein pp50, which are specific for (human leukocyte antigen) HLA class I.
      Pretreatment of the sample is simple and plasma can be stored, frozen, for a delayed dose of
      interferon.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Predictive values ​​of Cytomegalovirus infection</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>CMV infection defined by a positive ADNémie confirmed on a second sample ideally one week apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No response to treatment</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Persistence of an active CMV infection defined by a persistent ADNémie for more than 21 days under antiviral treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Renal Transplant Recipient</condition>
  <condition>Immunized Against the Cytomegalovirus.</condition>
  <arm_group>
    <arm_group_label>CMV infection</arm_group_label>
    <description>Renal transplant recipient immunized against the Cytomegalovirus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV Infection</intervention_name>
    <description>Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.
Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV.</description>
    <arm_group_label>CMV infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Detection of the CMV in sang, the leukocytes, or plasma with or without the viral
      quantification.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Renal transplant recipient Immunized against the Cytomegalovirus.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipient

          -  Immunized against the Cytomegalovirus

        Exclusion Criteria:

          -  Not willing to participate, no health insurance

          -  clinical evidence of active viral infection

          -  renal transplant recipient whose treatment includes induction antilymphocyte
             antibodies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie ALAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Limoges UH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie ALAIN, MD</last_name>
    <phone>05 55 05 67 28</phone>
    <email>sophie.alain@unilim.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sébastien HANTZ, MD</last_name>
    <phone>05 55 05 86 42</phone>
    <email>sebastien.hantz@unilim.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Amiens</city>
        <zip>80</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GAUDIO CASTELAIN Sandrine, MD</last_name>
      <phone>03 22 82 79 25</phone>
      <email>Sandrine.Castelain@u-picardie.fr</email>
    </contact>
    <investigator>
      <last_name>GAUDIO CASTELAIN Sandrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Angers</city>
        <zip>49</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra DUCANCELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra DUCANCELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Besancon</city>
        <zip>25</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COAQUETTE Alain, MD</last_name>
      <phone>03 81 21 88 80</phone>
      <email>alain.coaquette@ufc-chu.univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>COAQUETTE Alain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Brest</city>
        <zip>29</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie VALLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie VALLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Caen</city>
        <zip>14</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GOUARIN Stéphanie, MD</last_name>
      <phone>02 31 27 25 56</phone>
      <email>gouarin-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>GOUARIN Stéphanie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEIGUE-LAFEUILLE Hélène, MD</last_name>
      <phone>04 73 17 81 43</phone>
      <email>helene.lafeuille@u-clermont1.fr</email>
    </contact>
    <investigator>
      <last_name>PEIGUE-LAFEUILLE Hélène, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Dijon</city>
        <zip>21</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BOUR Jean-Baptiste, MD</last_name>
      <phone>03 80 29 38 56</phone>
      <email>jbbour@u-bourgogne.fr</email>
    </contact>
    <investigator>
      <last_name>BOUR Jean-Baptiste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GERMI Raphaële, MD</last_name>
      <phone>04 76 76 56 04</phone>
      <email>RGermi@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>GERMI Raphaële, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lille</city>
        <zip>59</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEWILDE Anny, MD</last_name>
      <phone>03 20 44 51 46</phone>
      <email>adewilde@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>DEWILDE Anny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bactériologie Virologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAIN Sophie, MD</last_name>
      <phone>05 55 05 67 24</phone>
      <email>sophie.alain@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>ALAIN Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MORFIN Florence, MD</last_name>
      <phone>04 78 77 70 26</phone>
      <email>florence.morfin-sherpa@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>MORFIN Florence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SEGONDY Michel, MD</last_name>
      <phone>04 67 33 71 27</phone>
      <email>m-segondy@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>SEGONDY Michel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nancy</city>
        <zip>54</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VENARD Véronique, MD</last_name>
      <phone>03 83 15 34 71</phone>
      <email>v.venard@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>VENARD Véronique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Nantes</city>
        <zip>44</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline BRESSOLLETTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline BRESSOLLETTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital SAINT-LOUIS</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Christine MAZERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Christine MAZERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital TENON - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick SOUSSAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick SOUSSAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Georges Pompidou - Virologie</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali SI MOHAMED, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ali SI MOHAMED, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie - Hôpital NECKER</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LERUEZ-VILLE Marianne, MD</last_name>
      <phone>01 44 49 62 64</phone>
      <email>marianne.leruez@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>LERUEZ-VILLE Marianne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BEBY-DEFEAUX Agnès, MD</last_name>
      <phone>05 49 44 38 15</phone>
      <email>a.beby-defaux@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>BEBY-DEFEAUX Agnès, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Reims</city>
        <zip>51</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny RENOIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fanny RENOIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Rennes</city>
        <zip>35</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MINJOLLE CHA Sophie, MD</last_name>
      <phone>02 99 28 42 76</phone>
      <email>Sophie.minjolle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>MINJOLLE CHA Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie PILLET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie PILLET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira FAFI-KREMER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samira FAFI-KREMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virologie</name>
      <address>
        <city>Tours</city>
        <zip>37</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GAUDY Catherine, MD</last_name>
      <phone>02 47 47 16 58</phone>
      <email>gaudy_c@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>GAUDY Catherine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>February 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal transplant</keyword>
  <keyword>CMV</keyword>
  <keyword>Test QuantiFERON-CMV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
